Search Page

1

Cite

Share

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Minor DR, Chin K, Kashani-Sabet M. Minor DR, et al. Among authors: chin k. Cancer Biother Radiopharm. 2009 Jun;24(3):321-5. doi: 10.1089/cbr.2008.0607. Cancer Biother Radiopharm. 2009. PMID: 19538054

Cite

Share

2

Cite

Share

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Apolo AB, et al. Among authors: chin k. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4. J Clin Oncol. 2017. PMID: 28375787 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Wolchok JD, et al. Among authors: chin k. Lancet Oncol. 2010 Feb;11(2):155-64. doi: 10.1016/S1470-2045(09)70334-1. Epub 2009 Dec 8. Lancet Oncol. 2010. PMID: 20004617 Clinical Trial.

Cite

Share

4

Cite

Share

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Hoos A, et al. Among authors: chin k. Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Semin Oncol. 2010. PMID: 21074069 Review.

Cite

Share

5

Cite

Share

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Wolchok JD, et al. Among authors: chin k. Ann Oncol. 2013 Aug;24(8):2174-80. doi: 10.1093/annonc/mdt161. Epub 2013 May 10. Ann Oncol. 2013. PMID: 23666915 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Slovin SF, et al. Among authors: chin k. Ann Oncol. 2013 Jul;24(7):1813-1821. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27. Ann Oncol. 2013. PMID: 23535954 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.

Sherrill B, Wang J, Kotapati S, Chin K. Sherrill B, et al. Among authors: chin k. Br J Cancer. 2013 Jul 9;109(1):8-13. doi: 10.1038/bjc.2013.298. Epub 2013 Jun 20. Br J Cancer. 2013. PMID: 23787916 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.

Chin K, Chand VK, Nuyten DSA. Chin K, et al. Ann Oncol. 2017 Jul 1;28(7):1658-1666. doi: 10.1093/annonc/mdx170. Ann Oncol. 2017. PMID: 28407031 Free PMC article. No abstract available.

Cite

Share

9

Cite

Share

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.

Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Gordon IO, et al. Among authors: chin k. Cancer Immunol Immunother. 2009 Aug;58(8):1351-3. doi: 10.1007/s00262-008-0627-x. Epub 2008 Dec 4. Cancer Immunol Immunother. 2009. PMID: 19052742 No abstract available.

Cite

Share

10

Cite

Share

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. Dirix LY, et al. Among authors: chin k. Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23. Breast Cancer Res Treat. 2018. PMID: 29063313 Free PMC article. Clinical Trial.

Cite

Share